Osimertinib and anti-HER3 combination therapy engages immune dependent tumor toxicity via STING activation in trans
Vicencio, J. M., Evans, R., Green, R., An, Z., Deng, J., Treacy, C., Mustapha, R., Monypenny, J., Costoya, C., Lawler, K., Ng, K., De-Souza, K., Coban, O., Gomez, V., Clancy, J., Chen, S. H., Chalk, A., Wong, F., Gordon, P., Savage, C., Gomes, C., Pan, T., Alfano, G., Dolcetti, L., Chan, J. N. E., Flores-Borja, F., Barber, P. R., Weitsman, G., Sosnowska, D., Capone, E., Iacobelli, S., Hochhauser, D., Hartley, J. A., Parsons, M., Arnold, J. N., Ameer-Beg, S., Quezada, S. A., Yarden, Y., Sala, G., Ng, T.
Published in Cell death & disease (28.03.2022)
Published in Cell death & disease (28.03.2022)
Get full text
Journal Article